Logo

Ciphergen Hires Emergo to Help Win CE Mark for Ovarian Cancer IVD

Dec 19, 2006
NEW YORK (GenomeWeb News) — Ciphergen has hired European international standards consulting company Emergo to help it win CE Mark clearance for its ovarian cancer in vitro diagnostic, the company said today.
 
The company said it also is preparing a clinical trial toward gaining clearance with the US Food and Drug Administration.
 
Under the agreement, Emergo will serve as a liaison with the European Ministries of Health to help Ciphergen earn Good Manufacturing Practices approval. Ciphergen said this will enable it to market the test in at least one European country in 2007.  
 
The test uses a panel of biomarkers that provide information that may help oncologists stratify risk of developing ovarian cancer. It would be used in medical triage for differentiating malignant and benign pelvic masses.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.